NCT06607627 - PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

April 16, 2027

Study Completion Date

July 18, 2029

Conditions

Generalized Myasthenia GravisgMG

Interventions

COMBINATION_PRODUCT

Gefurulimab

Combination product consisting of syringe prefilled with gefurulimab will be administered weekly via subcutaneous (SC) injection.

Trial Locations (12)

11101

RECRUITING

Research Site, Taipei

20010

RECRUITING

Research Site, Washington D.C.

23507

RECRUITING

Research Site, Norfolk

23561

RECRUITING

Research Site, New Taipei City

89202-451

RECRUITING

Research Site, Joinville

41253-190

RECRUITING

Research Site, Salvador

15090-000

RECRUITING

Research Site, São José do Rio Preto

0438-002

RECRUITING

Research Site, São Paulo

05403-000

RECRUITING

Research Site, São Paulo

85-086

NOT_YET_RECRUITING

Research Site, Bydgoszcz

93-338

NOT_YET_RECRUITING

Research Site, Lodz

02-097

NOT_YET_RECRUITING

Research Site, Warsaw